Abstract Details

Title Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Meta-analysis Comparing Tamsulosin with PGK1 Agonists, 5-ARI, and Other a-Blockers

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 3-020

Objective This meta-analysis aims to compare the risk of dementia in patients with benign prostatic hyperplasia (BPH) treated with tamsulosin or 5-α reductase inhibitors (5ARI), prostaglandin K1 receptor agonists (PGK1a), and other α-1 blockers.

Background Benign prostatic hyperplasia (BPH) is commonly treated with tamsulosin, an α1-adrenoceptor antagonist. However, recent studies have suggested that tamsulosin may increase the risk of dementia, while other interventions, including PGK1 agonists, have been associated with a protective factor for dementia.

Design/Methods

PubMed, Scopus and Web of Science databases were systematically searched until August 2024, for observational studies assessing the dementia risk in patients using 5ARI, PGK1 agonists, and α-1 blockers, including tamsulosin, for BPH. Hazard ratios (HR) were analyzed with 95% confidence intervals (CI). Heterogeneity was assessed using I² statistics. RStudio version 4.3.2 was used for statistical analysis.

Results A total of 3 observational studies including 1,280,008 patients were analyzed, of which 76,3% were diagnosed with dementia, and 23,7% were diagnosed with dementia with Lewy bodies (DLB) after treatment with 5ARI, PGK1 agonists or α-1 blockers for BPH. For DLB patients, there was a significant reduction in the risk of developing dementia with Lewy bodies for patients treated with tamsulosin, compared with 5ARI and PGK1 agonists (HR 0.63; 95% CI 0.53–0.76; P < 0.001; I² = 58%). In contrast, for general dementia, the treatment with tamsulosin resulted in a significantly increased risk, compared with 5ARI and other α-1 blockers (HR 1.13; 95% CI 1.03–1.23; P = 0.005; I² = 82%). In the general analysis, a statistically significant risk of dementia was not reached.

Conclusions In this meta-analysis, consistent results suggest that tamsulosin reduces the risk of DLB but increases the risk of general dementia compared to other therapies for benign prostatic hyperplasia.

Authors/Disclosures
Samuel Luca R. Pinheiro PRESENTER	Mr. Pinheiro has nothing to disclose.
Alice R. Silva, Medical student	Ms. Silva has nothing to disclose.
Rafael A. Aguiar	Mr. Aguiar has nothing to disclose.
Gabriel A. Araujo, Medical student	Mr. ARAUJO has nothing to disclose.
Antonia Campelo, Medical Student	Miss Campelo has nothing to disclose.
Lucas M. Linhares	Mr. Linhares has nothing to disclose.
Layla C. Benevides	Ms. Benevides has nothing to disclose.
LUIS H. REGO, Student	Mr. REGO has nothing to disclose.
Bianca V. Pinheiro	Miss Pinheiro has nothing to disclose.
Pedro L. Carvalho	Mr. Carvalho has nothing to disclose.
Artur Menegaz de Almeida, MS	Mr. Menegaz de Almeida has nothing to disclose.

��ɫ��

��ɫ��